The Business Times
business-time-50
BRUNCH
·
SUBSCRIBERS

新加坡生物科技的未来：与其追逐下一个“辉瑞”，不如专注创新

新加坡或许没有自己的行业巨头，但技术授权交易和早期突破仍可算作成功。

google-preferred-sourceAdd BT as a preferred source
Tessa Oh
Elysia Tan
Sharon See

Tessa Oh ,

Elysia Tan &

Sharon See

Published Fri, Nov 28, 2025 · 02:00 PM — Updated Mon, Dec 1, 2025 · 11:37 PM
    • 通过投资和再投资确保持续创新，新加坡能够脱颖而出。
    • 通过投资和再投资确保持续创新，新加坡能够脱颖而出。 插图：MARIO MONREAL、《商业时报》、ADOBE STOCK

    本文由AI辅助翻译

    查看原文

    [新加坡] 在这个城邦国家雄心勃勃地将生物医药科学打造为经济支柱的二十五年后，它尚未能孕育出一个像丹麦Novo Nordisk或美国Moderna那样规模的本土巨头。

    本地的生态系统拥有坚实的研究机构基础，以及涵盖从临床前到后期开发阶段的健康初创企业管线。然而，它仍未研发出一款重磅药物，也未能打造出一个能将成果从实验室推向市场的全球知名品牌。

    不过，它曾一度接近成功。2022年，Tessa Therapeutics作为一颗冉冉升起的新星，在A轮融资中成功筹集1.26亿美元，用于推进其癌症免疫细胞疗法的临床开发。

    Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

    此翻译对您是否有帮助？

    BrunchBiotechSingapore pharmaceuticalsSingapore economy

    Copyright SPH Media. All rights reserved.

    Reuse this contentFeedback

    TRENDING NOW

    The fourth Amity Circle retreat was hosted by Temasek Foundation from Apr 8 to 10 in Hanoi.

    Middle East-linked energy supply shocks put Asean Power Grid back in focus

    Leaders at the fifth Regional Comprehensive Economic Partnership (RCEP) Summit in Kuala Lumpur last October. The 10 Asean states, along with Australia, China, Japan, New Zealand and South Korea, are signatories to the trade pact.

    Strengthening Asean’s economic resilience through RCEP’s 2027 review

    Artificial intelligence is taking over many tasks, while young people find it difficult to hold their jobs.

    How China’s young workers are securing their future even as AI disrupts job market, triggers pay cuts

    US President Donald Trump (left) with Chinese President Xi Jinping in Busan in October 2025. The most plausible outcome of US-China rivalry is not a clean transition from one hegemon to another, but a fragmented order.

    US-China rivalry and the Kindleberger Trap: Why inaction – not escalation – is the biggest risk

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More